These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30910149)

  • 1. Effect of low-dose aspirin on the development of ovarian hyperstimulation syndrome and outcomes of assisted reproductive techniques in the women with PCOS, a randomized double-blinded clinical trial.
    Namavar Jahromi B; Zolghadri J; Rahmani E; Alipour S; Anvar Z; Zarei A; Keramati P
    Taiwan J Obstet Gynecol; 2019 Mar; 58(2):255-260. PubMed ID: 30910149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.
    Jacob SL; Brewer C; Tang T; Picton HM; Barth JH; Balen AH
    Hum Reprod; 2016 Dec; 31(12):2756-2764. PubMed ID: 27816925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of assistant treatment proposals for infertile women with polycystic ovary syndrome].
    Chen ZJ; Shi YH; Li Y; Gao Q; Sheng Y; Ma ZX
    Zhonghua Fu Chan Ke Za Zhi; 2008 Aug; 43(8):571-5. PubMed ID: 19087489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes.
    Cela V; Obino MER; Alberga Y; Pinelli S; Sergiampietri C; Casarosa E; Simi G; Papini F; Artini PG
    Gynecol Endocrinol; 2018 Jun; 34(6):518-523. PubMed ID: 29271274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myoinositol
    Rajasekaran K; Malhotra N; Mahey R; Khadgawat R; Kalaivani M
    Gynecol Endocrinol; 2022 Feb; 38(2):140-147. PubMed ID: 34590929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
    Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
    Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
    Zhu X; Ye H; Fu Y
    Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.